AstraZeneca Korea opposes price reduction of Iressa

Published: 2006-06-29 06:58:00

Updated: 2006-06-29 06:58:00

AstraZeneca Korea filed comments against the government's demand of price readjustment on the cancer drug Iressa (genfitinib) following a civic group's petition last March.

In its petition, the Health World Network argued that the insurance price of Iressa is higher than that prevailing in for...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK